Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status



Durable and sustained red blood cell...

Related Keywords

Johna Scarlett , ,Linkedin ,Drug Administration ,Exchange Commission ,Geron Corporation Nasdaq ,Malignant Hematology Department ,Moffitt Cancer Center ,Patient Support Program ,Geron Corporation ,Chief Executive ,Rami Komrokji ,Vice Chair ,Conference Call ,Eastern Time ,Prescribing Information ,Medication Guide ,Private Securities Litigation Reform Act ,Myelodysplastic Syndromes ,Emerging Therapeutic ,Cancer Manag ,